Servier/LinkedIn
Aug 9, 2025, 11:12
Promising R&D Pipeline Includes 36 Projects in Clinical Development
Servier shared on LinkedIn:
“Our promising R&D pipeline – focused mainly on oncology and now neurology – includes 36 projects in clinical development and 24 research projects resulting from significant and continuous R&D investment.
To date, 50% of the Group’s research projects have the potential to become first-in-class treatments (a drug with a new and unique mechanism of action).
Learn more about Servier.”
More posts featuring Servier.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 9, 2025, 11:37
Aug 9, 2025, 11:29
Aug 9, 2025, 11:12
Aug 9, 2025, 10:59
Aug 9, 2025, 10:52
Aug 9, 2025, 10:47
Aug 9, 2025, 10:38